Phase II trial with etoposide (VP16) plus ifosfamide plus high-dose cisplatin (VIhP regimen) in refractory germ cell tumors.
Droz
J P
JP
Department of Medicine, Institut Gustave-Roussy, Villejuif, France.
Ribrag
V
V
Ghosn
M
M
Guimares
J
J
Theodore
C
C
Azab
M
M
Ostronoff
M
M
Mahjoubi
M
M
Moran
A
A
Pico
J
J
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy*; D013736:Testicular Neoplasms / Q000188:drug therapy*
D005047:Etoposide; D002945:Cisplatin; D007069:Ifosfamide